BioStock: Cyxone attracts funding and files for new patents

In a short period of time, biotech company Cyxone has secured some 40 MSEK to fund the phase II study of Rabeximod in Covid 19-patients which is planned to start before year-end as well as other development activities. The capital raise has been conducted in two separate transactions, including a fully subscribed directed share issue of approximately 19 MSEK announced on November 10. Further, the company recently announced positive toxicological results for Rabeximod and has now also filed for extended patent protection with the European Patent Office (EPO).

Read the full article about Cyxone at biostock.se:

https://www.biostock.se/en/cyxone-attracts-funding-and-files-for-new-patents/
​​​​​​​ 
This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/